Gore髂分支内假体腔内修复主髂动脉及髂动脉瘤的前瞻性多中心6个月结果
IBE 12-04美国关键试验前瞻性纳入63例主髂动脉瘤或髂总动脉瘤患者,在28中心植入Gore髂分支内假体,6个月时髂内分支通畅率95.1%,无新发I/III型内漏或装置移位,IBE侧新发臀肌跛行0%。
要点
- IBE装置6个月髂内动脉分支通畅率95.1%,无新发I/III型内漏或移位。
- IBE侧新发臀肌跛行0%,对侧髂内动脉栓塞后跛行发生率28.6%。
- 技术成功率95.2%,无围手术期死亡,支持IBE保留髂内动脉血流。
核心结论
- IBE装置可有效治疗髂总动脉瘤和主髂动脉瘤,维持髂内动脉血流并避免牺牲髂内动脉相关并发症。
研究设计与样本
- 前瞻性多中心美国关键试验(IBE 12-04)纳入63例主髂动脉瘤或髂总动脉瘤患者,2013至2015年在28个中心植入单侧IBE装置。
- 22例(34.9%)双侧髂总动脉病变患者先期行对侧髂内动脉弹簧圈或封堵栓塞(21/22)或外科血运重建(1/22)。
- 随访30天和6个月,行临床评估和独立核心实验室判读的CTA评估。
主要发现
- IBE侧髂总动脉平均直径41.0±11.4 mm(范围25.2-76.3 mm)。
- 无围手术期死亡,技术成功率95.2%(60/63)。
- 61例可评估主要和次要终点,髂内分支通畅率95.1%(58/61),6个月无新发I/III型内漏或装置移位。
- 3例髂内分支通畅丧失患者均无症状,IBE侧6个月新发臀肌跛行豁免率100%。
- 对侧髂内动脉分期栓塞的21例中6例(28.6%)出现非IBE治疗侧新发臀肌跛行。
关键数值与推荐
- 主要有效性终点为6个月免于IBE分支闭塞、I/III型内漏再干预和≥60%狭窄。
- 次要有效性终点为6个月IBE侧免于新发臀肌跛行。
临床怎么用
- 对于主髂动脉瘤或髂总动脉瘤需腔内修复且需保留髂内动脉血流的患者,可考虑使用IBE装置。
- 双侧髂总动脉病变需行对侧髂内动脉栓塞时,应告知患者对侧臀肌跛行风险(28.6%)。
局限性
- 6个月随访数据,长期耐久性需持续随访5年确立。
- 样本量63例,主要终点可评估61例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The GORE EXCLUDER Iliac Branch Endoprosthesis (IBE; W. L. Gore and Associates, Flagstaff, Ariz) is an iliac branch stent graft system designed to preserve internal iliac artery perfusion during endovascular repair of aortoiliac aneurysms (AIAs) and common iliac artery (CIA) aneurysms (CIAAs). We report the 6-month primary end point results of the IBE 12-04 United States pivotal trial for endovascular treatment of AIAs and CIAAs using the IBE device. METHODS: The trial prospectively enrolled 63 patients with AIA or CIAA who underwent implantation of the IBE device at 28 centers in the United States from 2013 to 2015. All patients underwent placement of a single IBE device. Twenty-two patients (34.9%) with bilateral CIAs were enrolled after undergoing staged coil or plug embolization (21 of 22) or surgical revascularization (1 of 22) of the contralateral internal iliac artery. Follow-up at 30 days and 6 months included clinical assessment and computed tomography angiography evaluation as assessed by an independent core laboratory. The primary effectiveness end point was freedom from IBE limb occlusion and reintervention for type I or III endoleak and ≥60% stenosis at 6 months, and the secondary effectiveness end point was freedom from new onset of buttock claudication on the IBE side at 6 months. RESULTS: Mean CIA diameter on the IBE side was 41.0 ± 11.4 mm (range, 25.2-76.3 mm). There were no procedural deaths, and technical success, defined as successful deployment and patency of all IBE components and freedom from type I or III endoleak, was 95.2% (60 of 63). Data for 61 patients were available for primary and secondary effectiveness end point analysis. Internal iliac limb patency was 95.1% (58 of 61), and no new type I or III endoleaks or device migrations were observed at 6 months. The three patients with loss of internal iliac limb patency were asymptomatic, and freedom from new-onset buttock claudication on the IBE side was 100% at 6 months. New-onset buttock claudication occurred on the non-IBE treatment side in six of 21 patients (28.6%) who underwent staged internal iliac artery coil embolization. CONCLUSIONS: These results confirm that the IBE device is effective at treating CIAAs and AIAs, maintaining blood flow into the internal iliac artery, and avoiding complications associated with internal iliac artery sacrifice. Follow-up will be continued for 5 years to establish the long-term durability of iliac aneurysm repair with the IBE device.
引用
- Schneider DB, Matsumura JS, Lee JT, et al. Prospective, multicenter study of endovascular repair of aortoiliac and iliac aneurysms using the Gore Iliac Branch Endoprosthesis. J Vasc Surg. 2017. PMID: 28559174. doi:10.1016/j.jvs.2017.02.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。